The group of patients in the study examines PALLAS differs from the population that is used for the currently approved Multaq, patients who currently or not permanent atrial fibrillation. The study was conducted as part of the ongoing development program for Multaq. At the time the study was stopped 3149 patients were included.. The PALLAS study Multaq patients over 65 years patients over 65 years with permanent atrial fibrillation.
Click here for a download link to download the report in PDF find route.Sources: American Cancer Society.Written by: Catharine Paddock,European Medicines Agency reviews cardiovascular risk of MultaqThe European Medicines Agency is to review the cardiovascular risk of antiarrhythmic drug Multaq by Sanofi Aventis. This follows the company’s announcement on 7 July 2011, the abolition of the PALLAS study because of the occurrence of major cardiovascular events in some patients, the dronedarone.. Continue reading